RTA ‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma
The Kaohsiung Journal of Medical Sciences · 2026-06 · 42 (6)
DOI: 10.1002/kjm2.70142 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 28.11.2025. Verfasst von Hung-Pei Tsai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Glioblastoma, Radiation Tolerance, MAP Kinase Signaling System, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaohsiung Medical University Chung-Ho Memorial Hospital.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis owing to its high invasiveness and resistance to therapy. RTA‐408, a synthetic triterpenoid and nuclear factor erythroid 2‐related factor 2 activator, exhibits anti‐inflammatory and anti‐cancer properties; however, its effects on GBM remain unclear. This study investigated the therapeutic potential of RTA‐408 in GBM, focusing on its role in the activation of the JNK pathway. GBM8401 and A172 cells were treated with RTA‐408, and cell viability, apoptosis, migration, and radiosensitivity were assessed. Western blot analysis was used to evaluate the epithelial‐mesenchymal transition markers, cyclin D1, and JNK signaling. Intracranial xenograft models were used to assess tumor growth suppression by RTA‐408 alone or in combination with radiotherapy. RTA‐408 significantly reduced cell viability, induced apoptosis, and inhibited the migration of GBM cells, correlating with the activation of the JNK pathway. JNK inhibition reversed these effects, confirming its role in RTA‐408‐mediated tumor suppression. RTA‐408 also enhanced radiosensitivity and reduced clonogenic survival. RTA‐408 suppressed GBM tumor growth in vivo, with the greatest effect observed in combination with radiotherapy. RTA‐408 exerts antitumour and radiosensitizing effects via activation of the JNK pathway and inhibits GBM progression. These findings highlight its potential as a novel therapeutic strategy for the treatment of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Neurosurgery, Zaozhuang Municipal Hospital, Zaozhuang, China.
- Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
ORCID-Profile: Hung-Pei Tsai, Ann-Shung Lieu
Förderung
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Zitieren
APA
Tsai, H. P., Qin, H., Chong, Y. B., Chen, I. H., Kuo, S. H., Tseng, T. T., & Lieu, A. S. (2026). RTA ‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma. The Kaohsiung Journal of Medical Sciences, 42(6). https://doi.org/10.1002/kjm2.70142
Vancouver
Tsai HP, Qin H, Chong YB, Chen IH, Kuo SH, Tseng TT, et al. RTA ‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma. The Kaohsiung Journal of Medical Sciences. 2026;42(6). doi:10.1002/kjm2.70142
BibTeX
@article{Tsai2026,
author = {Tsai, Hung-Pei and Qin, Hao and Chong, Yoon Bin and Chen, I-Hsiang and Kuo, Shih-Hsun and Tseng, Tzu-Ting and Lieu, Ann-Shung},
title = {RTA ‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2026},
volume = {42},
number = {6},
doi = {10.1002/kjm2.70142}
}
EUVIMED